POLICY AND PROCEDURE

DEPARTMENT: Pharmacy Operations	**DOCUMENT NAME:** LINE EXTENSION ADDITIONS TO PDL
PAGE: 1 of 2	**REPLACES DOCUMENT:**
APPROVED DATE: 5/2016	**RETIRED:**
EFFECTIVE DATE: 5/2016	**REVIEWED/REVISED:** 11/16, 08/17
PRODUCT TYPE: Medicaid	**REFERENCE NUMBER:** CC.PHAR.15

SCOPE:
Centene Corporate Pharmacy Solutions, Health Plan Pharmacy Departments, ~~and~~ Envolve Pharmacy Solutions~~.~~

PURPOSE:
To describe how line extensions are assigned, identified, and placed on the preferred drug list (PDL).

POLICY:
Envolve Pharmacy Solutions will review new products when they first become available to determine line extensions. The decision will be provided to internal stakeholders including the rationale for placement of the new product. If there are safety or efficacy concerns for the product, then the line extension policy will not be applied.

PROCEDURE:

1. N~~The Medicaid Pharmacy Director receives updates of n~~ew product~~s~~s to the market will be~~and~~ reviewed~~reviews~~ by the drug information team. ~~for line extensions.~~
2. This review will be provided to the Strategy Development Committee (SDC) to determine if the product meets criteria for line extension or an established policy and procedure will be used for products that SDC does not review.~~A recommendation from the Medicaid Pharmacy Director will be provided within 1 week of the release of the product or drug monograph creation.~~
~~3.~~ The policies and procedures used to determine status of a product will be developed in the Formulary and Benefits (FAB) tool.~~A decision on the product will be made within 1 week of receiving the recommendation.~~
~~4.~~3. ~~Any request received outside of this process must be forwarded to the Medicaid Pharmacy Director for review.~~
~~5.~~4. D~~D~~ecisions on products being added as l~~s will be made on new products as l~~ine extensions to the PDL are based on the below considerations.
    a. If the new product is a new brand of an existing chemical entity, it will be non-PDL. The SDC will then consider it's placement on the PDL.
    b. If the new product is a new strength and same dosage form of an existing PDL product, line-extend off the existing product.
    c. If the new product is a new dosage form of a PDL drug, it will be non-PDL. The SDC will then consider it's placement on the PDL.
    d. If the new product is a non-first generic of a PDL drug, line-extend off the existing generics.
    e. If the new product is a vial, ampule, lancet, needle, or syringe, it will be non-PDL.
    f. If the new product is OTC, it will be non-PDL.

POLICY AND PROCEDURE

DEPARTMENT: Pharmacy Operations	**DOCUMENT NAME:** LINE EXTENSION ADDITIONS TO PDL
PAGE: 2 of 2	**REPLACES DOCUMENT:**
APPROVED DATE: 5/2016	**RETIRED:**
EFFECTIVE DATE: 5/2016	**REVIEWED/REVISED:** 11/16, 08/17
PRODUCT TYPE: Medicaid	**REFERENCE NUMBER:** CC.PHAR.15

g. If the new product is a multi-source brand (MSB), it will be non-PDL.
h. If the new product is a new chemical entity, it will be reviewed by the ~~D~~drug i~~I~~nformation team ~~for recommendation to Medicaid Director on potential addition to the PDL~~. The SDC will then consider it's placement on the PDL.
i. If the new product is a cough and cold generic product, it will be reviewed against current PDL cough and cold generic products for line extension.
j. If the new product is a vitamin, it will be reviewed against current PDL vitamins for line extension.
k. If the new product is a prenatal vitamin, it will be reviewed by the AWP cost of the drug. If the new prenatal vitamin's cost is ≤ $15, it will be PDL.
l. If the new product is a lancet and costs ≤ $0.07, it will be PDL.
m. If the new product is an alcohol swab and costs ≤ $0.04, it will be PDL.
~~j.~~n. If the new product are needles and cost ≤ $0.40, it will be PDL.
~~k.~~o. If the new product is durable medical equipment (DME), it will be non-PDL.
~~l.~~p. If the new product is a flu vaccine, it will be reviewed for line-extension on current PDL flu vaccines.
~~m.~~q. If the new product is a new pen or auto-injector, it will be non-PDL. The SDC will then consider it's placement on the PDL.
r. If the new product is a combination of existing products, it will be non-PDL. The SDC will then consider it's placement on the PDL.
~~n.~~s. If the new product is a prescription drug that has changed to an OTC drug, SDC will consider it's placement on the PDL.
t. If the new product is a re-packaged product, it will be non-PDL.
~~o.~~u. If the new product is a new package size of an existing PDL drug, it will be non-PDL.

REFERENCES: N/A

ATTACHMENTS: N/A

Formatted: Font: Not Bold

DEFINITIONS:
PDL - Preferred Drug List
OTC – Over The Counter
MSB - Multi-Source Brand
DME – Durable Medical Equipment
SDC - Strategy Development Committee
AWP – Average Wholesale Price

POLICY AND PROCEDURE

DEPARTMENT: Pharmacy Operations	**DOCUMENT NAME: LINE EXTENSION ADDITIONS TO PDL**
PAGE: 3 of 3	**REPLACES DOCUMENT:**
APPROVED DATE: 5/2016	**RETIRED:**
EFFECTIVE DATE: 5/2016	**REVIEWED/REVISED:**
PRODUCT TYPE: Medicaid	**REFERENCE NUMBER:** CC.PHAR.15

REVISION LOG

REVISION	DATE
Changed US Script to Envolve Pharmacy Solutions	11/16
Added SDC to definitions; updated 1-4 of the procedure to the new process; added that SDC determines addition of drug to PDL for certain drugs; added the status of a new package size of a PDL drug; added that a new prenatal vitamin will be added to the PDL if the AWP is ≤ $15; added AWP to definitions; added if the new product is a prescription drug that has changed to an OTC, SDC will consider it's placement on the PDL; added the AWP cost of lancets, alcohol swabs, and needles for PDL addition.	08/17

POLICY AND PROCEDURE APPROVAL

Pharmacy & Therapeutics Committee: Approval on file

V.P., Pharmacy Operations: Approval on file

SR. V.P. Medical Affairs or Chief Medical Officer: Approval on file

NOTE: The electronic approval is retained in Compliance 360.